Andelyn Biosciences Capacity Update May 2024: Cell & Gene Therapy
Source: Andelyn Biosciences
With the FDA pushing platform approach as a pathway to enabling more rare disease therapies, they also acknowledge the importance of process parameter adjustments specific to individual transgenes. In this presentation from the May 2024 OPCU event, learn how Andelyn's proven methodology and decades-long AAV database at the core of the AAV Curator™ Platform directly drives speed, maximizes yields, and ensures a high-quality product is delivered and manufactured reliably.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.
Subscribe to Drug Discovery Online
X
Subscribe to Drug Discovery Online
Andelyn Biosciences
This website uses cookies to ensure you get the best experience on our website. Learn more